Post

Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis. According to …

Denosumab biosimilar by Lupin for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Lupin and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, …

23ME610 by 23AndMe Holding for Merkel Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23AndMe Holding and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData, …

23ME610 by 23AndMe Holding for Metastatic Renal Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23AndMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma. According to …

Sarilumab by Regeneron Pharmaceuticals for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval

Sarilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Polyarticular Juvenile Idiopathic Arthritis (PJIA). According to …